Education
About Us
Working with TipRanks
Follow Us
Siegfried Holding AG (SGFEF)
OTHER OTC:SGFEF
Earnings Data
Report Date
Aug 20, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.02Last Year’s EPS
1.94Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: record profitability, margin expansion to ~23.5%, strong cash generation, major strategic investments and an accretive U.S. acquisition that strengthens the network. Management also highlighted robust commercial momentum (RFP wins +30%), quality and safety improvements, and concrete sustainability progress. Key risks discussed were a material pending confirmation on one large on‑market Drug Substance product (creating cautious Drug Substance guidance for 2026), meaningful currency headwinds, and near‑term top‑line timing/seasonality and elevated investment-related ramp timing. On balance, the strengths — sustainable margin improvement, cash and balance sheet flexibility, M&A that increases strategic optionality, and clear commercial momentum — outweigh the near‑term uncertainties.Company Guidance
Revenue Growth and Scale
Group sales of CHF 1.33 billion in FY2025, up 4.3% in local currency; both Drug Substance and Drug Product grew +4.3% LFL, with H2 accounting for ~53% of revenue.
Record Profitability and Margin Expansion
Core EBITDA margin reached 23.5% with core EBITDA of CHF 312.3 million (+9.3% year-over-year); core gross profit of CHF 354 million (+7.6%). Management targets core EBITDA margin above 23% for 2026.
Strong Cash Generation and Balance Sheet Flexibility
Operating cash flow improved (operating cash flow up ~35% YoY); strategic financing actions included a CHF 300 million bond and a non-recourse factoring facility (CHF 40 million used of a CHF 50 million facility). Net debt/EBITDA was ~1.5x at year-end pre-acquisition and improved to ~1.0x after receivables converted to cash.
Active Capital Deployment for Growth
Investments (tangible + intangible) totaled CHF 231 million in 2025 to expand capacity and capabilities; management expects capex to normalize to low-teens % of sales going forward.
Successful M&A to Strengthen U.S. Footprint
Announced acquisition of Noramco/Extractas (U.S. sites) to add large-scale CDMO capacity in the U.S.; management indicated purchase price is below a ~10x EBITDA multiple and expects immediate top- and bottom-line contribution upon closing and additional upside from freed capacity and synergies.
Commercial Momentum and Business Development
RFP inflows and wins increased ~30% in 2025 vs 2024 (more projects/new customers across both Drug Substance and Drug Product); multiple new program wins including three protein degrader programs won in the prior 5 weeks.
Operational and Quality Achievements
Lost-time injury frequency improved by 25%; 6 of 13 sites certified on Class A project; successfully passed four FDA audits in 2025 and DINAMIQS passed Swissmedic GMP inspection recently, enabling GMP production.
Sustainability Progress
Progress toward sustainability targets with roughly ~50% reductions in CO2 and energy use compared to 2020 levels.
Extraordinary Recovery
One‑time recovery of CHF 7.5 million relating to a 2021 fraudulent payment was recorded as other operating income.
Shareholder Return & Financial Management
Board proposed distribution via par value repayment of CHF 0.4 per share; management emphasized disciplined capital allocation and retained firepower for further M&A if attractive targets appear.
SGFEF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGFEF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 20, 2026 | $104.61 | $104.61 | 0.00% |
Aug 21, 2025 | $114.35 | $114.35 | 0.00% |
Feb 18, 2025 | $117.52 | $109.77 | -6.59% |
Aug 22, 2024 | $102.77 | $102.77 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Siegfried Holding AG (SGFEF) report earnings?
Siegfried Holding AG (SGFEF) is schdueled to report earning on Aug 20, 2026, Before Open (Confirmed).
What is Siegfried Holding AG (SGFEF) earnings time?
Siegfried Holding AG (SGFEF) earnings time is at Aug 20, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGFEF EPS forecast?
SGFEF EPS forecast for the fiscal quarter 2026 (Q2) is 2.02.